Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Share-based Compensation (2018 - 2025)

Neurogene's Share-based Compensation history spans 6 years, with the latest figure at $3.4 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 35.18% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $14.2 million, up 70.47%, while the annual FY2025 figure was $14.2 million, 70.47% up from the prior year.
  • Share-based Compensation reached $3.4 million in Q4 2025 per NGNE's latest filing, roughly flat from $3.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.0 million in Q1 2025 to a low of $293000.0 in Q1 2023.
  • Average Share-based Compensation over 3 years is $2.3 million, with a median of $2.5 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: soared 600.56% in 2024, then skyrocketed 35.18% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $355000.0 in 2023, then skyrocketed by 600.56% to $2.5 million in 2024, then surged by 35.18% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Share-based Compensation are $3.4 million (Q4 2025), $3.4 million (Q3 2025), and $3.4 million (Q2 2025).